Towards a personalised clinical management of oncologic patients with acute kidney injury associated to immunecheckpoint inhibitors

Lombady partner:

- Laura Cosmai, ASST Fatebenefratelli Sacco

Pathology of interest:

  Acute kidney injury

 Area of research:


 Start date:

  01 April 2023

 End date:

  31 March 2026


  € 102.800,00

 Project partners:

 Nephrology Dept., Hospital Vall d’Hebron. Vall d´Hebron Institut   de Recerca (VHIR), Barcelona, Spain

 Department of Nephrology Dialysis and Internal Medicine,   Medical University of Warsaw, Poland

 Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Italy

 Department of Nephrology and Hypertension, Hannover Medical   School, Germany

 Dept. of Automatic Control, Universitat Politècnica de Catalunya (UPC), Spain

 Department of Public Health and Caring Sciences, Uppsala   Biomedical Centre, Uppsala University, Sweden

 Faculty of Medicine, Bezmialem Vakif University, Turkey

Treatment with immune checkpoint inhibitors (ICIs) has led to increased survival rates of cancer patients, who were previously untreatable, by favouring an immune response against tumour cells. ICIs action is not selective and may cause immune-related adverse events. Up to 29% of cancer patients, who receive ICIs treatment, develop acute kidney injury (AKI) secondary to ICIs use (ICI-AKI), and acute tubulointerstitial nephritis (ATIN) is the most frequent lesion. ICI-AKI is a serious complication that increases the risk of AKI recurrence after ICIs rechallenge and mortality. The diagnosis of ICI-AKI is performed by a kidney biopsy, which is highly invasive. We will collect retrospective and prospective demographic and clinical data of ICI-AKI patients as well as urine, blood and kidney tissue samples of ICI treated cancer patients during two years to identify novel biomarkers related to immune response to avoid kidney biopsy. This approach will allow personalising clinical management of these patients and improving their quality of life.